Pages that link to "Q27851711"
Jump to navigation
Jump to search
The following pages link to Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. (Q27851711):
Displaying 50 items.
- Mutational profiling of kinases in glioblastoma (Q21261249) (← links)
- BRAF V600E (Q21851559) (← links)
- Opposing activities of the Ras and Hippo pathways converge on regulation of YAP protein turnover (Q24303432) (← links)
- Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas (Q24303940) (← links)
- Markers of resistance to anti-EGFR therapy in colorectal cancer (Q24598640) (← links)
- Treatment of Metastatic Colorectal Cancer: Standard of Care and Future Perspectives (Q26738801) (← links)
- Genomic diversity of colorectal cancer: Changing landscape and emerging targets (Q26739052) (← links)
- Molecular Subtypes and Personalized Therapy in Metastatic Colorectal Cancer (Q26747329) (← links)
- Practical aspects of NGS-based pathways analysis for personalized cancer science and medicine (Q26748603) (← links)
- Serrated colorectal cancer: Molecular classification, prognosis, and response to chemotherapy (Q26751035) (← links)
- Advances in targeted and immunobased therapies for colorectal cancer in the genomic era (Q26751344) (← links)
- Tumour Cell Heterogeneity (Q26765895) (← links)
- Colorectal cancer tumour markers and biomarkers: Recent therapeutic advances (Q26768427) (← links)
- Novel therapeutic agents in the treatment of metastatic colorectal cancer (Q26769932) (← links)
- Clinical efficacy and drug resistance of anti-epidermal growth factor receptor therapy in colorectal cancer (Q26769958) (← links)
- Somatic DNA mutation analysis in targeted therapy of solid tumours (Q26770324) (← links)
- Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer (Q26771952) (← links)
- BRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapies (Q26772276) (← links)
- New therapeutic strategies for BRAF mutant colorectal cancers (Q26772277) (← links)
- Lung cancer biomarkers, targeted therapies and clinical assays (Q26775396) (← links)
- Treatment Individualization in Colorectal Cancer (Q26776215) (← links)
- Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials (Q26776394) (← links)
- Molecular profiling in the treatment of colorectal cancer: focus on regorafenib (Q26778296) (← links)
- BRAF Mutation in Colorectal Cancer: An Update (Q26781926) (← links)
- Therapy for BRAFi-Resistant Melanomas: Is WNT5A the Answer? (Q26782222) (← links)
- Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance (Q26795609) (← links)
- Current and future molecular profiling of cancer by next-generation sequencing (Q26796272) (← links)
- Combination Therapies to Inhibit the RAF/MEK/ERK Pathway in Melanoma: We are not Done Yet (Q26799864) (← links)
- Cancer Cell Line Panels Empower Genomics-Based Discovery of Precision Cancer Medicine (Q26800337) (← links)
- Using large-scale genomics data to identify driver mutations in lung cancer: methods and challenges (Q26800833) (← links)
- New and emerging factors in tumorigenesis: an overview (Q26801253) (← links)
- Tumor-Derived Cell Lines as Molecular Models of Cancer Pharmacogenomics (Q26801410) (← links)
- Personalized treatment for advanced colorectal cancer: KRAS and beyond (Q26822817) (← links)
- Toward a Molecular Classification of Colorectal Cancer: The Role of BRAF (Q26827212) (← links)
- Acquired and intrinsic resistance in cancer immunotherapy (Q26827701) (← links)
- Cancer heterogeneity--a multifaceted view (Q26829228) (← links)
- Adaptive resistance to targeted therapies in cancer (Q26849316) (← links)
- Ten things you should know about protein kinases: IUPHAR Review 14 (Q26849417) (← links)
- The minority report: targeting the rare oncogenes in NSCLC (Q26851636) (← links)
- Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies (Q26852049) (← links)
- Time to re-consider the meaning of BRAF V600E mutation in papillary thyroid carcinoma (Q26853261) (← links)
- Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance (Q26866517) (← links)
- Tumour heterogeneity and the evolution of polyclonal drug resistance (Q26866803) (← links)
- How many molecular subtypes? Implications of the unique tumor principle in personalized medicine (Q26992045) (← links)
- Molecular Technologies in the Clinical Diagnostic Laboratory (Q26996463) (← links)
- The next steps in next-gen sequencing of cancer genomes (Q26998894) (← links)
- Resistance to receptor tyrosine kinase inhibition in cancer: molecular mechanisms and therapeutic strategies (Q27004161) (← links)
- Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma (Q27013006) (← links)
- In vitro and in vivo models for analysis of resistance to anticancer molecular therapies (Q27014174) (← links)
- Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (Q27015224) (← links)